论文部分内容阅读
作者叙述了93例用同一方法治疗的急淋患儿的临床特征和治疗结果。这些病人已作4年随访(中数),且在这些病人中用三种细胞表面标记在表型上确定了急淋的亚型,这三种标记是人类 T 细胞抗原(HTA)、免疫相关抗原(Ia)和普通急淋抗原(CALLA)。其中,11人属 T 细胞组(HTA~+Ia~-CALLA~-),77人属非 T 细胞组(Ia~+HTA~-)。Ia~+组中有43人的细胞可供抗 CALLA 试验,结果36人 CALLA~+,7人 CA-LLA~-。另5例病人有少见的表面标记。一人是 HTA-Ia~+CALLA~+,在4个 HTA~-Ia~-的病人中3人有足够
The authors describe the clinical features and treatment outcomes of 93 cases of acute leucorrhea treated with the same method. These patients have been followed for 4 years (median) and in these patients the acute leuko subtypes were phenotypically identified using three cell surface markers. These three markers are human T cell antigen (HTA), immune-related Antigen (Ia) and common acute antigen (CALLA). Among them, 11 were in the T cell group (HTA~+Ia~CALLA~-) and 77 were in the non-T cell group (Ia~+HTA~-). In the Ia~+ group, 43 cells were available for the anti-CALLA test, resulting in 36 CALLA~+ and 7 CA-LLA~-. The other 5 patients had rare surface markings. One person was HTA-Ia~+CALLA~+, and 3 of 4 HTA~-Ia~- patients had enough